Dr. Gregory Poland, infectious diseases expert and head of Mayo Clinic’s Vaccine Research Group.
COVID-19 vaccination for children under 12 is one step closer to reality.
Pfizer announced it submitted data of their phase 2 and phase 3 trial of their COVID-19 in children ages 5–11 to the Food and Drug Administration (FDA). A formal submission to request emergency use authorization (EUA) of the company’s COVID-19 vaccine in children in this age group is expected in the coming weeks.
The FDA will need to analyze data before a decision is made.
“There is thinking we will see an emergency use authorization approval for children ages 5 to 11 years old before Halloween,” says Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic’s Vaccine Research Group.